Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H24FN7O.ClH |
Molecular Weight | 481.953 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)N1C=NN=C1C2=CC=CC(NC(=O)C3=CC(N4C=NC(=C4)C5CC5)=C(C)C=C3F)=N2
InChI
InChIKey=DQKKBHINKKMQHS-UHFFFAOYSA-N
InChI=1S/C24H24FN7O.ClH/c1-14(2)32-13-27-30-23(32)19-5-4-6-22(28-19)29-24(33)17-10-21(15(3)9-18(17)25)31-11-20(26-12-31)16-7-8-16;/h4-6,9-14,16H,7-8H2,1-3H3,(H,28,29,33);1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C24H24FN7O |
Molecular Weight | 445.4921 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.gilead.com/news/press-releases/2016/4/gilead-presents-new-data-highlighting-progress-in-liver-fibrosisCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800040265
https://www.ncbi.nlm.nih.gov/pubmed/25531162
Sources: http://www.gilead.com/news/press-releases/2016/4/gilead-presents-new-data-highlighting-progress-in-liver-fibrosis
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800040265
https://www.ncbi.nlm.nih.gov/pubmed/25531162
Selonsertib, also known as GS-4997, is a small-molecule inhibitor of apoptosis signal-regulating kinase 1 (ASK1), which promotes inflammation, apoptosis and fibrosis in settings of increased oxidative stress associated with NASH pathogenesis. GS-4997 prevents the production of inflammatory cytokines, down-regulates the expression of genes involved in fibrosis, suppresses excessive apoptosis and inhibits cellular proliferation. GS-4997 is currently being evaluated in an ongoing Phase 2 study in patients with NASH and moderate to severe liver fibrosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5285 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25531162 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02177786
Selonsertib tablets 2 mg, 6 mg, 18 mg for 48 weeks, administered orally once daily.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:18:26 GMT 2023
by
admin
on
Sat Dec 16 10:18:26 GMT 2023
|
Record UNII |
A24IO3O2HW
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
A24IO3O2HW
Created by
admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
|
PRIMARY | |||
|
300000013051
Created by
admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
|
PRIMARY | |||
|
71654746
Created by
admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
|
PRIMARY | |||
|
1448428-05-4
Created by
admin on Sat Dec 16 10:18:26 GMT 2023 , Edited by admin on Sat Dec 16 10:18:26 GMT 2023
|
PRIMARY |